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costs. In the US, the family members’ aggregate productivity loss was estimated 
at $3.3 billion. Spouses of prostate cancer patients were found to have incurred 
$1,309 in lost productivity. Spouses’ aggregate productivity loss was estimated at 
$1.3 billion. Sensitivity analysis of the aggregated US estimates revealed that the 
total lost productivity of family members as a result of prostate cancer ranged 
from $2.2 billion to $4.6 billion. For spouses of prostate cancer patients, the 
results of the sensitivity analysis ranged from $0.9 billion to $1.7 billion. 
CONCLUSIONS: These findings indicate that prostate cancer has a significant 
impact on work productivity of prostate cancer patients’ families and spouses. 
However, there are few resources available to assist prostate cancer patients and 
families in dealing with the disease from a psychosocial aspect. Research is 
warranted to further assess the negative effects of prostate cancer on families.  
 
PCN46  
STANDARD TREATMENT COST OF BREAST CANCER WITH DIFFERENT TNM 
STAGE AMONG WESTERN CHINESE WOMEN  
Huang Y, Li JY 
West China School of Public Health, Sichuan University, Chengdu, China  
OBJECTIVES: To obtain the standard treatment cost of female breast cancer with 
different TNM Stage. METHODS: The treatment cost of female breast cancer 
consisted of direct medical expenditure, direct non-medical expenditure, and 
indirect expenditure. Extracting previous data, calculating by clinical pathway, 
face-to-face interviewing, and telephone interviewing were adopted to estimate 
the treatment cost of female breast cancer; ANOVA and SNK were performed to 
detect the significantly differences in treatment cost with different TNM stages. 
RESULTS: Direct medical expenditure was extracted from medical record and 
expense statement of 316 breast cancer cases in Sichuan Cancer Hospital; direct 
non-medical expenditure was investigated from 59 patients and their relatives; 
indirect expenditure was surveyed from 94 cases who received surgery more 
than one year ago. The average treatment cost of female breast cancer was 
RMB154,658 (US$24,854), which was adjusted by the proportions of ER, PR, and 
menses status of patients. The range of treatment cost from TNM 0 stage to TNM 
IV stage is RMB37,608-RMB207,824 (US$6,044-US$33,397). Breast cancer cases 
with early stage had considerably lower treatment cost than those with 
advanced stage. CONCLUSIONS: Early detection and treatment of breast cancer 
may have a real economic significance for reducing the burden of disease.  
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OBJECTIVES: Studies have shown that men diagnosed with metastatic prostate 
cancer report significantly reduced quality of life (QoL) and have higher levels of 
depression and anxiety than men with localized prostate cancer. The present 
study assessed the impact of prostate cancer on health-related QoL compared to 
individuals without prostate cancer. METHODS: Using 1996-2009 data from the 
Medical Expenditure Panel Survey (MEPS), multivariate analyses were performed 
on three health status measures: 1) EuroQol EQ-5D, 2) Short Form (SF)-12 Health 
Survey, 3) Self-reported health status. All men age 40 and older with 
International Classification of Disease Codes, 9th revision of 185 were identified. 
RESULTS: The MEPS database included 1,399 patients with prostate cancer. Mean 
age was 72 years, and 71% were Caucasian. The EQ-5D results indicated that QoL 
was 5% lower for prostate cancer patients than individuals without prostate 
cancer (0.76 vs. 0.80, p < 0.001). Results of the SF-12 Physical Health Composite 
Scores (PCS) indicated that prostate cancer patients scored lower than 
individuals without prostate cancer (44.6 vs. 46.3 [population norm = 50],  
p < 0.001). Prostate cancer patients also rated themselves 12% lower on the self-
reported physical health status than individuals without prostate cancer (0.69 vs. 
0.78, p < 0.001). There was no significant difference in mental health of prostate 
cancer patients as measured by the SF-12 Mental Health Composite Score or self-
reported mental health status. CONCLUSIONS: These findings indicate that 
prostate cancer has a significant negative effect on physical health as measured 
by the EQ-5D, the SF-12 PCS, and patient self-report. Prostate cancer had no 
discernible effect on patients’ mental health. Further research on the effects of 
disease severity on QoL is warranted as literature indicates that there are few 
psychosocial interventions for patients with advanced disease.  
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OBJECTIVES: Patients diagnosed with metastatic (M1) prostate cancer (PCa) are 
predisposed to skeletal related events (SREs), including bone surgery (BS), 
pathologic fracture (PF) and spinal cord compression (SCC). There is limited 
information regarding the change in costs associated with SREs, by type, among 
stage IV M1 PCa patients. METHODS: We analyzed patients aged 66+ with an 
(AJCC) M1 PCa diagnosis. Cases diagnosed between 2000 and 2007 were identified 
from the Surveillance, Epidemiology, and End Results (SEER)-Medicare dataset. 
Patients were followed until death or censoring. Incremental costs per patient 
were calculated for the 12-month pre-period and the 12-month post-period 
relative to the first post-diagnosis SRE. Results were reported as the average 
percent change in the total pre-post period costs. Subgroup analysis was carried 
out separately for individuals who survived (survivors) and died (non-survivors) 
within the 12-month post-period. A sensitivity analysis was carried out for a  
6-month pre-post interval. The analysis was conducted from a US Medicare 
system perspective. RESULTS: Application of inclusion criteria resulted in 1,234 
stage IV M1, PCa patients with SREs. The average age was 78 years and 11% were 
African American. Five, mutually exclusive SRE groups were evaluated: PF-only 
(n=180), SCC-only (n=634), BS-only (n=200), PF with BS (n=163), SCC with BS 
(n=57). The average percent increase in the total costs in the post-period 
compared to the pre-period was 67%. The average percent increases in costs for 
each of the subgroups were as follows: PF-only, 53%; PF with BS, 71%; SCC-only, 
64%; SCC with BS, 88%; and BS-only, 70%. Subgroup analysis showed a 77% 
increase in total costs among survivors and a 60% increase in costs among non-
survivors. The average percent increase in SRE costs using a pre-post period of 6 
months was 75%. CONCLUSIONS: The percentage increase in costs post-SRE 
varies by type of SRE, survival post-SRE, and interval length.  
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OBJECTIVES: Costs for the population of metastatic castrate-resistant prostate 
cancer (mCRPC) patients can be difficult to discern due to the lack of a specific 
International Classification of Diseases, 9th Revision (ICD-9) code. This study 
described the resource utilization and costs of patients with mCRPC in a large US 
health claims database using chemotherapy administration as a proxy. 
METHODS: Data from January 1, 2006-June 30, 2011 from the MarketScan 
Commercial and Medicare databases were used in this analysis. Index date was 
defined as the first docetaxel, mitoxantrone, estramustine, vinorelbine, 
cabazitaxel or abiraterone treatment date between January 1, 2007 and June 30, 
2010. Additional inclusion criteria: >=18 years old; continuous pharmaceutical 
and medical enrollment >=6 months prior to and >=2 months following the index 
date; >=1 ICD-9 diagnosis code for prostate cancer (185.x). mCRPC related costs 
were identified by the presence of an ICD-9 code of 185.x on the claim. Costs 
were estimated separately for chemotherapy, radiation, inpatient, outpatient 
and emergency room (ER). Median per patient per month (PPPM) costs were 
calculated at the patient level. RESULTS: 4,005 patients were eligible, with a 
mean age of 70.2 years. For patients with medical utilization, total median PPPM 
costs increased from $3,107 pre-index to $6,939 post-index. Chemotherapy costs 
increased ($234 pre-index vs. $1,439 post-index), while radiation costs decreased 
($793 vs. $394). Excluding costs related to chemotherapy, radiation and other 
drug treatment, costs for inpatient, outpatient and ER visits increased from 
$2,120 pre-index to $4,388 post-index. Both mCRPC-related costs ($862 vs. $1,986) 
and non-mCRPC-related costs ($763 vs. $1,628) rose. CONCLUSIONS: These 
findings indicate that the cost burden from mCRPC is quite large. With aging of 
the population, prevalence of prostate cancer is expected to increase to 3.2 
million in the US by 2020 with costs continuing to escalate. Further research is 
needed to understand these cost implications, especially for the Medicare 
system.  
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OBJECTIVES: To assess the clinical burden, health care utilization, and cost 
patterns of prostate cancer patients in the U.S. veteran population. METHODS: A 
retrospective database analysis was performed using the Veterans Health 
Administration (VHA) Medical SAS Datasets from October 1, 2005 to May 31, 2012. 
All U.S. veteran beneficiaries diagnosed with prostate cancer were identified 
using International Classification of Disease 9th Revision Clinical Modification 
(ICD-9-CM) diagnosis code 185.xx. Descriptive statistics were calculated as 
means ± standard deviation (SD) and percentages to measure clinical, cost, and 
utilization distribution in the sample. The most common comorbidities and 
treatment medications for prostate cancer patients were also examined. 
RESULTS: Among all study patients diagnosed with prostate cancer (n=251,890), 
the most common comorbidities were hypertension (n=69,534, 27.60%), elevated 
prostate-specific antigen (PSA) levels (n=45,498, 18.06%), and diabetes (n=34,171, 
13.57%). The most common treatment medications prescribed for prostate 
cancer patients were simvastatin (n=71,263, 28.29%), omeprazole (n=34,185, 
13.57%) and terazosin hydrochloride (n=22,639, 8.99%). A total of 117,599 (46.69%) 
patients had PSA test results, with an average result of 14.26. Percentages of 
inpatient (12.89%), emergency room (ER) (13.12%), physician office (99.86%), 
outpatient visits (99.87%), and pharmacy visits (90.34%) were calculated. Patient 
expenditures were found to be $4,227 (SD=$28,254) for inpatient, $146 (SD=$582) 
for ER, $6,469 (SD=$11,387) for physician office, $6,781 (SD=$11,837) for outpatient 
visits and $1,247 (SD=$4,159) for pharmacy visits. CONCLUSIONS: PSA laboratory 
test results should be considered when evaluating disease severity and 
progression of prostate cancer. However, the effects of prescribed medications 
on those test results should always be considered when interpreting laboratory 
results.  
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OBJECTIVES: To present nationally representative estimates of the impact of 
cancer survivorship on medical expenditures and lost productivity among adults 
in the United States. METHODS: Using the 2008-2010 Medical Expenditure Panel 
Survey we identified 4,960 cancer survivors and 64,431 individuals without a 
history of cancer aged ≥18 years. Direct medical costs were measured using 
annual health care expenditures and examined by source of payment and 
service type. Indirect morbidity costs were estimated from the lost productivity 
due to health-related unemployment, missed work days, and lost household 
productivity. We evaluated the economic burden of cancer survivorship by 
estimating the excess costs among cancer survivors compared with individuals 
without a history of cancer using multivariable regression models stratified by 
age (18-64 and ≥65 years) while controlling for age, gender, education, and 
comorbidities. RESULTS: In 2008-2010, the annual excess economic burden of 
cancer survivorship was $7,631 per cancer survivor aged 18-64 years and $5,445 
per survivor aged ≥65 years. Excess direct medical expenditures comprised the 
largest share, with excess annual medical expenditures of $5,570 and $4,683 
among cancer survivors aged 18-64 years and ≥65 years, respectively. 
Ambulatory care accounted for the largest share of medical expenditures in both 
groups. The largest source of payment was private health insurance for cancer 
survivors aged 18-64 years, and Medicare for cancer survivors aged ≥65 years. 
Cancer survivors aged 18-64 years incurred an excess annual productivity loss of 
$2,061 per individual while cancer survivors aged ≥65 years reported an excess 
annual lost productivity of $762 per individual. CONCLUSIONS: The economic 
burden of cancer survivorship is substantial, resulting in excess health care 
expenditures and lost productivity costs compared with individuals without a 
history of cancer. Efforts to reduce the economic burden caused by cancer will be 
increasingly important given the growing population of cancer survivors.  
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OBJECTIVES: To estimate the incremental health care costs associated with 
adverse events (AEs) among metastatic melanoma (MM) patients treated with 
seven commonly used therapies. METHODS: Retrospective health care claims 
from the Marketscan® commercial and Medicare supplemental databases were 
examined from June 1, 2004 to April 30, 2012. Patients included those ≥18 years 
who had diagnosed melanoma (ICD-9 code: 172.xx) with at least one diagnosis of 
metastasis within 30 days prior to or 60 days after any melanoma diagnosis, and 
≥ one claim for any of the following MM treatments: paclitaxel, vemurafenib, 
ipilimumab, dacarbazine, temozolomide, high dose interleukin-2, or interferon 
alpha. AE categories of interest included cardiovascular, CNS/psychiatric, 
metabolic disorders, gastrointestinal, hemic/lymphatic disorders, pain, and 
skin/subcutaneous events that occurred after initiation of therapy. Health care 
encounters for AEs were based on ICD-9-CM diagnosis/procedure codes on 
health care claims. The incremental cost per AE was determined by comparing 
the 30-day expenditures in patients with the event to patients without the event 
based on a 30-day shadow event date. Drug costs of the MM therapies were 
excluded from the analysis. Multivariate generalized linear models (GLM) with a 
log-link function and gamma distribution were utilized to control for differences 
in baseline characteristics between groups. RESULTS: A totla of 2621 MM 
patients were included in this analysis. Mean age was 56.0 years (SD: 13.0), 64% 
were male and 24% had a diagnosis of primary or secondary brain cancer at the 
time of MM diagnosis. The GLM-based estimate of 30-day incremental costs by 
AE category were: metabolic, $9,135 (95% CI: $6,404-$12,392); hemic/lymphatic, 
$8,450 ($6,528-$10,633); cardiovascular, $6,476 ($4,667-$8,541); gastrointestinal, 
$6,338 ($4,740-$8,122); skin/subcutaneous, -$900 (-$1,899- $237); CNS/psychiatric, 
$5,903 ($3,842-8,313); and pain, $5,078 ($3,392-$7,012). CONCLUSIONS: The 
incremental costs associated with AEs therapies to treat MM are substantial. 
New approaches to prevent and/or better manage these events may reduce 
overall health care costs.  
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OBJECTIVES: To characterize real-world medical resource utilization and costs 
following initiation of anti-cancer treatments for patients with Stage IB-IV Non-
Small Cell Lung Cancer (NSCLC). METHODS: A retrospective, longitudinal, open-
cohort study design was chosen using Medicare linked Surveillance 
Epidemiology and End Results (SEER) data. All Medicare-eligible patients in the 
SEER registry who were diagnosed with NSCLC during 2005–2007 and treated 
with anti-cancer therapy were identified. The observation period spanned from 
NSCLC diagnosis through the earliest date of end of anti-cancer therapy, data 
end date, or death. All-cause and NSCLC-related utilization and costs were 
reported, stratified by hospitalization, emergency room (ER), and outpatient 
visits. Results were stratified by patients with non-advanced cancer (Stages IB-
IIIA) and advanced cancer (Stages IIIB-IV). Pharmacy costs were reported for 
patients diagnosed with NSCLC in 2007. RESULTS: The study population 
consisted of 6,365 patients; mean (SD) age was 73.7 (5.4) years, 54% were males, 
and median follow-up was 351 days. The all-cause rate per patient per month 
(PPPM) was 0.14, 0.10, and 4.08; NSCLC-related PPPM rate was 0.12, 0.05, and 2.86 
for hospitalization, ER, and outpatient, respectively. The median monthly length 
of stay (days) for hospitalization was 1.25 for all-cause and 1.0 for NSCLC-related 
stays. The mean all-cause PPPM costs were $4,989 (hospitalization: $2,278, ER: 
$54, outpatient: $2,657). The mean NSCLC-related PPPM costs were $4,032 
(hospitalization: $1,721, ER: $23, outpatient: $2,288). The mean all-cause PPPM 
costs were $3,805 ($2,873 NSCLC-related) for patients with non-advanced cancer 
and $5,822 ($4,847 NSCLC-related) for patients with advanced cancer. All-cause 
PPPM prescription drug costs were $560. CONCLUSIONS: The SEER-Medicare 
database analysis found that in Stage IB-IV NSCLC patients, NSCLC-related costs 
accounted for over 80% of all health care costs while patients were on anti-
cancer therapies. Higher costs were incurred by patients diagnosed with 
advanced NSCLC as compared to patients diagnosed with non-advanced disease.  
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OBJECTIVES: Despite major advances, resistance and intolerance continue to be 
a significant challenge in the management of CML. This study evaluated the real-
world resource use and costs associated with CML treatment failure with 
dasatinib or nilotinib (defined as treatment switch or discontinuation) from a US 
payer perspective. METHODS: This was a retrospective study using the IMS 
PharMetrics health plan claims database from July 2006-June 2011. Adult patients 
with CML diagnosis (ICD-9 205.1x) with ≥1 fill of dasatinib or nilotinib were 
selected. Failure was defined as a switch to another tyrosine kinase inhibitor 
(TKI) or a gap in index TKI >90 days. Direct medical resource use and costs (2011 
USD) were measured for those with 6 months of continuous enrollment post-
failure, including all-cause medical and pharmacy costs. RESULTS: 608 CML 
patients were identified initiating dasatinib or nilotinib, of which 290 
experienced treatment failure. Of these, 192 had 6 months of continuous 
enrollment post-failure. Average age was 57.5 years and 55.7% were female. 
Mean 6-month costs post-failure were $79,996 (median $33,100), with inpatient 
costs comprising 54.4%, followed by pharmacy (23.1%) and outpatient (22.2%). 
During the 6 months post-failure, one-third of patients had at least one 
hospitalization (median 12 days) with leukemia being the most frequent primary 
diagnosis for hospitalization, 22% had an emergency room visit, 96% had 
physician office visits (median 11 visits), with a median of 27 lab tests and 20 
prescription fills per person (median 16 non-TKI fills). CONCLUSIONS: The 6-
month economic burden of failure from nilotinib and dasatinib is substantial and 
is largely due to the disease. The availability of new agents to effectively manage 
this hard-to-treat population has the potential to improve costs of care by 
preventing disease progression.  
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OBJECTIVES: To determine the usage and costs of oral cancer treatment in 
elderly Medicare Part D beneficiaries. METHODS: A cross-sectional retrospective 
study was conducted using a 5% random sample of 2008 Medicare beneficiaries. 
The study sample included all members of this group who: 1) were 65 years of 
age and older and 2) filled at least one prescription for imatinib, erlotinib, 
anastrozole, letrozole, or thalidomide.We examined the average costs patients 
paid per day, the cost that the Part D plan paid per day, and total cost for the 
entire year for each drug. We determined the percentage of enrollees who 
entered the Part D coverage gap, the time, and duration that they fell into the 
coverage gap. RESULTS: Prescription drug subsidy was categorized in four 
groups: 1) Dual Eligible (DE); 2) full Low Income Subsidy (LIS); 3) partial LIS; and 4) 
no subsidy. Mean out-of-pocket (OOP) costs per day were between $0.03 and 
$0.09 for DE beneficiaries, between $0.04 and $0.22 for full LIS beneficiaries, 
between $1.17 and $6.34 for partial LIS beneficiaries,and between $2.92 and 
$36.83 for beneficiaries who did not receive a subsidy. About 99% of users of the 
more expensive drugs - imatinib, erlotinib and thalidomide - entered the 
coverage gap and the majority of these entered the coverage gap at the time of 
their first fill. In contrast, beneficiaries who filled the less expensive drugs - 
anastrozole and letrozole- entered the coverage gap later. Beneficiaries who used 
imatinib, erlotinib, or thalidomide spent approximately a month in the coverage 
gap. The majority of their time was spent in the catastrophic phase. 
CONCLUSIONS: Beneficiaries receiving subsidies had low OOP costs, averaging 
between $0.03 and $6.34 per day. Beneficiaries on the more expensive drugs and 
not having subsidies had high OOP costs, averaging between $15.66 and 36.83 per 
day.  
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OBJECTIVES: The rising costs of cancer care are a major focus for clinicians, 
payers and patients. This analysis describes changes in location of 
chemotherapy administration and reimbursement, highlighting areas for 
potential policy changes METHODS: Using the MarketScan©Research Databases, 
administrations of bevacizumab and trastuzumab were identified from January 
